Amgen and its Big Pharma partner AstraZeneca have roped in another round of promising Phase III plaque psoriasis data for their IL-17 blockbuster contender brodalumab, which beat Johnson & Johnson’s big earner Stelara in a head-to-head study.

…read more

Source: Amgen and AstraZeneca’s psoriasis drug beats blockbuster Stelara in head-to-head trial


0 No comments